corticosteroids'therapy

Phase 3Small molecule

UUniversity Hospital, Rouen

corticosteroids'therapy is one of 22 small molecule programs targeting Pemphigus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PemphigusActive, not recruiting

PemphigusPhase 3

Active, not recruiting

Competition

Competitive Landscape

24 competitors in Pemphigus

#DrugCompanyPhaseTrials

Imuran

LLegacy Health System

Rayos

2 3

Vyvgart

Argenx

Phase 3

2 4

Wayrilz

GGenzyme, a Sanofi Company

Phase 3

1 5

Mabthera

Pfizer

Phase 3

1 6

NOVOLIN R

Novo Nordisk

Phase 2

1 7

Cytoxan

BBaxter Healthcare Corporation

Phase 2

2 8

Neupogen

EEastern Cooperative Oncology Group

Phase 2

1 9

Decadron

AAspen Global Incorporated

Phase 2

1 10

Glucocorticoids

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pemphigus1 trial

Clinical and Immunological Long-term Follow-up of Patients With Pemphigus Included in the "RITUXIMAB 3" Trial

Completed·UUniversity Hospital, Rouen·Phase 3·NCT03790293·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for corticosteroids'therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — corticosteroids'therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for corticosteroids'therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Rouen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity Hospital, Rouen

corticosteroids'therapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pemphigus1 trial

References

Drug Info

Quick Facts

Related News